SAN DIEGO, CA — January 28, 2026 — Leads & Copy — Spruce Biosciences, Inc. (Nasdaq: SPRB) has announced that data on the long-term administration of its tralesinidase alfa enzyme replacement therapy (TA-ERT) for the treatment of Sanfillipo syndrome type B (MPS IIIB) will be presented at the 22nd Annual WORLDSymposium™ taking place February 2-6, 2026 in San Diego.
A second presentation will detail divergent outcomes in two male siblings, one of whom was treated with TA-ERT in a clinical trial while the other received care without treatment.
Nicole Muschol, M.D., International Center for Lysosomal Disorders (ICLD) at the University Medical Center Hamburg-Eppendorf in Germany, will present data on the long-term administration of tralesinidase alfa enzyme replacement therapy (TA-ERT). The presentation will focus on the profound and durable reduction of heparan sulfate (HS) and stabilization of cognitive function and cortical gray matter volume (CGMV) in patients with Sanfilippo syndrome type B (MPS IIIB). The presentation is scheduled for February 5, 2026, from 1:42 – 1:54 p.m. PT in the Harbor Ballroom.
The authors of this presentation include Nicole Muschol, M.D.; Mona Lindschau, M.D.; Ilyas Okur, M.D.; Fatih Ezgu, M.D.; Maria J. de Castro Lopez, M.D.; Spyros Batzios, M.D.; Igor Nestrasil, M.D.; Saba Sile, M.D.; Ting Chang, Ph.D.; Jeffrey Zhang, Ph.D.; Javier Szwarcberg, M.D., M.P.H.; and Paul Harmatz, M.D.
These data will also be presented as poster #259 on February 5 from 3:30 – 5:30 p.m. PT at Kiosk 30-B.
Irene J. Chang, M.D., Assistant Professor at the University of California, San Francisco, will present a poster on divergent neurocognitive outcomes in mucopolysaccharidosis (MPS) type IIIB siblings, comparing tralesinidase alfa versus supportive management. The poster presentation (#64) is scheduled for February 5, 2026, from 3:30 – 5:30 p.m. PT at Kiosk 8-C.
The authors of this poster include Irene J. Chang, M.D.; Jacqueline Madden, P.N.P.; Erin Jozwiak, N.P.; Saba Sile, M.D.; Ting Chang, Ph.D.; Javier Szwarcberg, M.D., M.P.H.; and Paul Harmatz, M.D.
Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need.
Source: Spruce Biosciences
